CommercialCoverageLow impact
Isturisa (osilodrostat)
Blue Cross & Blue Shield of Mississippi·MS · Endocrinology, Neurosurgery, Oncology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi updated their policy on Isturisa (osilodrostat) for Cushing's disease, maintaining that it is considered not medically necessary due to other covered treatment options. The policy clarifies that drug samples cannot be used to satisfy medical policy requirements and services without prior authorization will be denied.
Action Required
Immediately: Billing team must verify formulary coverage for any Isturisa prescriptions through patient's member ID before billing. Ensure prior authorization is obtained through BCBSMS PA review process before any related services. Document that samples cannot be used to meet policy requirements for medical necessity determinations.